- MEDIUM
- Business
- Tier 1
- Hard News
vVardis targets $4.4 billion valuation in US IPO
- Source
- Becker's Dental + DSO Review
- Author
- Ariana Portalatin
- Originally at
- beckersdental.com(opens in a new tab)
Summary and scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol. Not the original publisher.
Why it matters for dental
vVardis's planned IPO and growth in U.S. sales of its noninvasive decay-repair product could expand treatment options and supplier competition for dental practices adopting non-drill protocols.
Key points
- 01
vVardis filed to raise up to $228.6 million through a U.S. IPO targeting a valuation of up to $4.37 billion.
- 02
Curodont Repair Fluoride Plus generated 112% sales growth in the nine months ended.
- 03
As of June 30, the product had been sold to more than 20,000 U.S. dental practices.
- 04
Apollo Global Management funds made a strategic minority investment in vVardis in April.
Who should care
- Owner
- DSO
Read the original
Becker's Dental + DSO Review
Full reporting and any paywalled content live on beckersdental.com. We summarize and score; we do not republish.